Pharmaceutical research services provider Charles River Laboratories International Inc (NYSE:CRL) and Akron Bio, a supplier of critical materials and services for advanced therapies, on Thursday announced the integration of Akron's CGMP liquid cytokines into Charles River's Cell Therapy Flex Platform.
This collaboration aims to streamline cell therapy manufacturing operations by enabling closed system processing.
The integration will enhance process robustness and minimise risk by incorporating ready-to-use liquid cytokines into automated platforms.
These cytokines, including rHu IL-2, IL-7, IL-15 and IL-21, are crucial for optimising CAR-T and TCR-T cell therapies.
Biophytis signs co-development agreement with AskHelpU for ALS in China
Nanobiotix reports first patient dosed in Phase 2 lung cancer study
Takeda's FRUZAQLA receives Health Canada market authorisation for metastatic colorectal cancer
InnoCare and KeyMed license CD20xCD3 bispecific antibody to Prolium
GSK's Jemperli receives expanded EU approval for endometrial cancer treatment
AstraZeneca's Datroway approved in US for HR-positive breast cancer
Amgen's LUMAKRAS (sotorasib) in combination with Vectibix (panitumumab receives US FDA approval
Guangzhou Fermion Technology partners with Simcere Pharmaceutical
Zai Lab submits New Drug Application for KarXT to treat schizophrenia in China
Telix Pharmaceuticals' Illuccix gets European approval
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
RYBREVANT approved in Canada for second-line EGFR-mutated lung cancer
Charles River and Akron Bio collaborate to enhance cell therapy manufacturing
Avacta Group reports positive data from AVA6000 Phase 1 trial in salivary gland cancer